Dr. Takeshima@Web

    Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, et al.  A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.  Expert Opinion on Drug Safety. 2022:1-8.  

   Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, et al.  Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.  Brain Behav. 2022;12(3):e2526. https://www.ncbi.nlm.nih.gov/pubmed/35201674 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933787/pdf/BRB3-12-e2526.pdf 2022/02/25